^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/13/2023
Excerpt:
Soft tissue sarcoma....Subsequent Lines of Therapy for Advanced/Metastatic Disease, category 2A, Useful in certain circumstances recommendation:...Pembrolizumab or Nivolumab ± ipilimumab...For TMB-H (≥10 mutations/megabase [mut/Mb])l regardless of soft tissue sarcoma sub-type
